PURPOSE:To investigate serologic evidence of infection by cytomegalovirus (CMV), a herpesvirus with known oncogenic potential that has been detected in malignant prostate tissue, in relation to prostate cancer (PCa) risk in a large case-control study nested in the Prostate Cancer Prevention Trial (PCPT).
METHODS:Cases were men with a confirmed diagnosis of PCa after visit 2 (n = 614), and controls were men not diagnosed with PCa during the trial who also had a negative end-of-study biopsy (n = 616). Controls were frequency-matched to cases by age, treatment arm, and family history of PCa. Sera from visit 2 were tested for CMV IgG antibodies.
RESULTS:No association was observed between CMV serostatus and PCa risk (adjusted CMV seroprevalence = 67.9 % for cases and 65.2 % for controls, odds ratio = 1.13, 95 % CI 0.89-1.45).
CONCLUSIONS: Considering our null findings in the context of the full CMV literature, CMV infection, as measured by serostatus, does not appear to increase PCa risk.
Written by:
Sutcliffe S, Till C, Gaydos CA, Jenkins FJ, Goodman PJ, Hoque AM, Hsing AW, Thompson IM, Zenilman JM, Nelson WG, De Marzo AM, Platz EA. Are you the author?
Division of Public Health Sciences and the Alvin J. Siteman Cancer Center, Department of Surgery, Washington University School of Medicine, 660 S. Euclid Ave., Rm. 5026, Box 8100, St. Louis, MO, 63110, USA.
Reference: Cancer Causes Control. 2012 Sep;23(9):1511-8.
doi: 10.1007/s10552-012-0028-5
PubMed Abstract
PMID: 22810146
UroToday.com Prostate Cancer Section
